Business
US Patent Allowance: SDC-1802 TYK2/JAK1 Inhibitor
US Patent Allowance: SDC-1802 TYK2/JAK1 Inhibitor.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 4377B\n Sareum Holdings PLC\n 08 October 2020\n \n \n \n \n SAREUM HOLDINGS PLC\n \n \n (\"Sareum\" or \"the Company\")\n \n \n US Patent Allowance for Sareum's SDC-1802 TYK2/JAK1 Inhibitor\n \n \n Cambridge, UK, 8 October 2020\n - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent in respect of an invention associated with Sareum's proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme (the \"SDC-1802 Programme\"). This programme is in preclinical development and targets cancer and cancer immunotherapy.\n \n \n The patent (US Patent Application no. 16/351,620) will protect the SDC-1802 molecule and pharmaceutical preparations thereof. Subject to certain formalities being completed, the Company expects that the patent will be granted within three months. Following the grant of this patent, Sareum will have approved patent protection in the US for its SDC-1802 Programme and the grant will complete the patent protection for this programme across all major territories. This follows similar patent protection being granted to the Company in Europe, announced on 10 November 2014, and in Japan and China, announced on 19 December 2017.\n \n \n Sareum's CSO, Dr John Reader, commented\n : \n \n \n \"The granting of this patent in the US will complete the protection of the intellectual property for our proprietary SDC-1802 Programme across all major markets. The Board believes that the patent will enhance the value of its TYK2/JAK1 inhibitor programmes and the Company's negotiating position as it continues to engage in discussions with potential licence partners.\"\n \n \n This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014.\n \n \n For further information, please contact: \n \n \n Sareum Holdings plc\n \n \n Tim Mitchell, CEO 01223 497 700\n \n \n Strand Hanson Limited (Nominated Adviser)\n \n \n James Dance / Richard Tulloch 020 7409 3494\n \n \n Hybridan LLP (Nominated Bro...